Literature DB >> 2510163

Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution.

T Miyata1, S Kawabata, S Iwanaga, I Takahashi, B Alving, H Saito.   

Abstract

Structural studies on a congenital abnormal coagulation factor XII (Hageman factor), factor XII Washington D.C., have been performed to identify the defect responsible for its lack of procoagulant activity. Amino acid sequence analysis of a tryptic peptide isolated from the abnormal factor XII indicated that Cys-571 (equivalent to Cys-220 in the chymotrypsin numbering system) had been replaced by serine. No other substitutions in the active-site triad--namely, His-393, Asp-442, and Ser-544--were found. We propose that the Cys-571----Ser replacement found in this factor XII variant destroys the formation of the disulfide linkage between Cys-540 and Cys-571, giving rise to an altered conformation of the active-site serine residue or the secondary substrate-binding site and, thus, leads to the loss of enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510163      PMCID: PMC298272          DOI: 10.1073/pnas.86.21.8319

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+).

Authors:  H Saito; J G Scott; H Z Movat; S J Scialla
Journal:  J Lab Clin Med       Date:  1979-08

2.  Determination of the amino acid sequence of porcine trypsin by sequenator aalysis.

Authors:  M A Hermodson; L H Ericsson; H Neurath; K A Walsh
Journal:  Biochemistry       Date:  1973-08-14       Impact factor: 3.162

3.  Substrate binding site in bovine chymotrypsin A-gamma. A crystallographic study using peptide chloromethyl ketones as site-specific inhibitors.

Authors:  D M Segal; J C Powers; G H Cohen; D R Davies; P E Wilcox
Journal:  Biochemistry       Date:  1971-09-28       Impact factor: 3.162

4.  Activation of bovine factor XII (Hageman factor) by plasma kallikrein.

Authors:  K Fujikawa; R L Heimark; K Kurachi; E W Davie
Journal:  Biochemistry       Date:  1980-04-01       Impact factor: 3.162

Review 5.  The biochemistry and pathophysiology of the contact system of plasma.

Authors:  C G Cochrane; J H Griffin
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

Review 6.  Surface-mediated reactions.

Authors:  O D Ratnoff; H Saito
Journal:  Curr Top Hematol       Date:  1979

7.  A gas-liquid solid phase peptide and protein sequenator.

Authors:  R M Hewick; M W Hunkapiller; L E Hood; W J Dreyer
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

8.  Properties of sulfatides in factor-XII-dependent contact activation.

Authors:  G Tans; J H Griffin
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

9.  Isolation and properties of an abnormal Hageman factor (Factor XII) molecule in a cross-reacting material-positive hageman trait plasma.

Authors:  H Saito; S J Scialla
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  The binding of bovine factor XII to kaolin.

Authors:  E P Kirby; P J McDevitt
Journal:  Blood       Date:  1983-04       Impact factor: 22.113

View more
  3 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  Allosteric control of βII-tryptase by a redox active disulfide bond.

Authors:  Kristina M Cook; H Patrick McNeil; Philip J Hogg
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

3.  A novel 5'-upstream mutation in the factor XII gene is associated with a TaqI restriction site in an Alu repeat in factor XII-deficient patients.

Authors:  S Hofferbert; J Müller; H Köstering; W D von Ohlen; M Schloesser
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.